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generic revolution is still ahead and the drug market as a whole
will be deeply affected by an increasing number of generic drugs.
Public policy should take into account this evolution, in order to
maintain the industry capacity to innovate.
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OBJECTIVES: The number of economic evaluation studies has
grown extensively in recent years. However, a limited number of
studies investigated its impact on decision making; the gap is par-
ticularly evident in Italy where there are no such studies avail-
able. Objective of the research is to evaluate impact of economic
evaluation analysis on decision making in the Italian health care
system. The prospective taken is that of professionals operating
within the system. The aim is to investigate whether there are
evident differences in attitudes among professionals who conduct
different types of activities. METHODS: A 12 item based ques-
tionnaire was sent to 374 health care professionals who had
undergone some form of health economics training. The sample
was taken from a list of participants of a major health care man-
agement program at Bocconi School of Management in the last
10 years. RESULTS: Response rate was 35%. All respondents
stated that basics of economic evaluation analysis must be part
of the overall knowledge of health care professionals. Grade of
usefulness of these arguments in professional activities was rated
3.84 (scale 1–5). Respondents considered that economic evalua-
tion is more largely used in making managerial types of decisions
rather than clinical ones (mean 2.94 vs. 2.73). Decisions taken
according to short-term perspectives are considered the major
barrier in the use of economic evaluation studies, particularly 
by managers (71%). More training in health economics was 
indicated as the most relevant facilitating factor for a wider use
of studies, by both clinicians and managers (64%). Majority of
respondents (80%) considered that the maximum beneﬁts of eco-
nomic evaluation are taken from its use at the organizational
level. CONCLUSIONS: Although economic evaluation has a
rather modest impact on decision making in Italian health care,
there are some encouraging signs that could lead to its wider and
more effective use.
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OBJECTIVES: In Korea, even non-prescription drugs have been
on the list of reimbursable drugs, but recent suggestions are that
there is a need to change the scope of the positive list. In April
2002, 829 non-prescription alimentary tract drugs were removed
from the list of reimbursable drugs and made non-reimbursable
even when doctors prescribed them. This study investigated the
effect of delisting on the prescribing pattern of alimentary tract
drugs. METHODS: Health insurance reimbursement claims data
before (October 2001) and after (October 2002, October 2003)
the delisting were analyzed for 707 clinics (4% randomized sam-
pling). We calculated the prescription rate of alimentary tract
drugs and examined the use of alimentary tract drugs by dis-
eases. RESULTS: The prescription rate for alimentary tract drugs
declined from 79.03% in October 2001 to 59.91% in October
2002 and to 61.58% in October 2003. The prescription rate for
digestives, of which all products were delisted, dropped sharply
from 32.03% before delisting to 1.9% in October 2002 and to
0.75% in October 2003. Medicines for intestinal disorders were
prescribed less frequently after delisting, while the prescription
rate for anti-ulcerants and antacids increased by 3–4%. In
general, the drugs on the positive list were not switched to
delisted drugs, even though some listed ingredients were used
more often. Also, the use of alimentary tract drugs for patients
who had respiratory diseases such as common cold reduced more
than by 20% after delisting, while the prescription rate for those
with gastric ulcer decreased by 1% after delisting. CONCLU-
SIONS: The delisting policy reduced the use of alimentary tract
drugs. But there was difference in the effect of  delisting by drug
classiﬁcation and some delisted drugs were found to be switched
to listed drugs. The use of alimentary tract drugs changed less
for diseases for which they are essential than for supplementary 
purposes.
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OBJECTIVES: The Dutch Ministry of Health (MoH) has
requested the Health Care Insurance Board (CVZ) to advise on
the modernisation of the drug reimbursement system
(Geneesmiddelenvergoedingssysteem GVS). On behalf of the
CVZ, PharMerit assessed the impact of market competition on
pricing and reimbursement (P&R) of patented drugs in Belgium,
France and Germany. METHODS: In-depth interviews with
reimbursement policy-makers; analysis of laws and policy docu-
ments. Impact of market competition (deﬁned as total number
of marketed generics and therapeutically comparable patented
drugs) on drug reimbursement decision-making was assessed in
each of the study countries. RESULTS: In Belgium and France,
drug P&R is determined in negotiation between manufacturers
and authorities. Generic prices are set 30–40% lower than spe-
cialties. “Late-arrivals” (e.g. me-too’s or other therapeutically
comparable patented drugs) receive lower prices than (ﬁrst-in-
class) “early-arrivals”. Since 2004, patented drugs in Germany
are no longer excluded from therapeutic reference-pricing if at
least 3 comparable alternatives are available. Sickness Funds are
legally entitled to adjust cluster reference prices in case justiﬁed
by “changes in the market”. Cluster reference prices with a high
number of generics (off-patent and patented drugs) are expected
to be reduced in the future. Prices of patented late-arrivals in The
Netherlands are not directly subject to market competition con-
siderations and tend to level the cluster reference price, based 
on the average price of clustered products. Recently, prices of
generics have been lowered in an informal agreement between
MoH and manufacturers. The MoH is seeking ways to mod-
ernise the reimbursement system. CONCLUSIONS: In Belgium
and France, late-arriving patented drugs can be assigned rela-
tively lower prices in comparison to their early-arriving com-
petitors. In Germany, introduction of late-arrivals may impact
on P&R of both early and late-arrivals. In the current set-up of
the Dutch GVS, market introduction of late-arrivals does not
impact on cluster reference prices.
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OBJECTIVES: Reimbursement policies clearly affect the ratio-
nal use of drugs. In Turkey there are three state funded social
